Orexo AB has announced that it sold Abstral (fentanyl) Sublingual Tablets in the United States to Galena Biopharma, Inc. Under...
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
Orexo AB have regained from 1 January 2013 US rights to market Abstral (fentanyl citrate sublingual) from Kyowa Hakko Kirin/ProStraken....
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the...
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...